Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac

Jesús A. Junco*, Ranfis Rodríguez², Franklin Fuentes¹, Idania Baladrón³, Maria D. Castro¹, Lesvia Calzada¹, Carmen Valenzuela⁴, Eddy Bover³, Eulogio Pimentel³, Roberto Basulto¹, Niurka Arteaga¹, Angel Cid-Arregui², Francisco Sariol⁶, Lourdes González⁸, Liliana Porres-Fong⁶, Maria Medina⁶, Ayni Rodríguez⁶, A. Hilda Garay⁸, Osvaldo Reyes³, Matilde López², Lourdes de Quesada⁸, Allelin Alvarez⁶, Carolina Martínez⁶, Marleny Marrero⁶, Guillermo Molero⁶, Alfredo Guerra⁶, Pedro Rosales⁶, Carlos Capote⁶, Sahily Acosta⁸, Idania Vela⁶, Lina Arzuaga⁶, Ana Campal¹, Erlán Ruiz⁶, Elier Rubio⁶, Pável Cedeño⁶, Maria Carmen Sánchez⁶, Pedro Cardoso⁶, Rolando Morrán¹, Yairis Fernández⁶, Magaly Campos⁶, Henio Touduri⁷, Dania Bacardi³, Indalecio Feria¹⁰, Amilcar Ramirez⁶, Karelia Cosme³, Pedro López Saura³⁷, Maricel Quintana³, Verena Muzio³, Ricardo Bringas³, Marta Ayala³, Mario Mendoza¹, Luis E. Fernández⁴, Adriana Carr⁴, Luis Herrera³,¹¹ and Gerardo Guillén³

Heberprovac is a GnRH based vaccine candidate containing 2.4 mg of the GnRhm1-TT peptide as the main active principle; 245 µg of the very small size proteoliposomes adjuvant (VSSP); and 350 µL of Montanide ISA 51 VG oil adjuvant. The aim of this study was to assess the safety and tolerance of the Heberprovac in advanced prostate cancer patients as well as its capacity to induce anti-GnRH antibodies, the subsequent effects on serum levels of testosterone and PSA and the patient overall survival. The study included eight patients with histologically-proven advanced prostate cancer with indication for hormonal therapy, who received seven intramuscular immunizations with Heberprovac within 18 weeks. Anti-GnRH antibody titers, testosterone and PSA levels, as well as clinical parameters were recorded and evaluated. The vaccine was well tolerated. Significant reductions in serum levels of testosterone and PSA were seen after four immunizations. Castrate levels of testosterone were observed in all patients at the end of the immunization schedule, which remained at the lowest level for at least 20 months. In a 10-year follow-up three out of six patients who completed the entire trial survived. In contrast only one out eight patients survived in the same period in a matched randomly selected group receiving standard anti-hormonal treatment.
INTRODUCTION

The early landmark studies of Huggins and Hodges established the hormonal dependence of prostate cancer and provided the basis for the use of androgen deprivation in its treatment (1).

Reduction of plasma testosterone to castrate levels, either through surgical castration (orchietomy), or of oral or injectable estrogens, became the standard therapy for disseminated prostate cancer in the following 40 years (2–6). In the early 1980s, LHRH analogs were added as an alternative to achieve reversible pharmacologic castration (7–10).

By the mid 1990’s, an immunological approach (LHRH vaccines) had been designed and tested in men to achieve androgen deprivation to treat prostate cancer (11, 12) and in post-menopausal women to test gonadotropin inhibition (13). The efficacy of the neutralizing action of LHRH/GnRH through the involvement of hormone-specific antibodies has been demonstrated in a wide range of animal species, including humans. Such studies have involved either passive immunization by infusion of anti-LHRH antibodies (14) or vaccination with the LHRH peptide coupled to tetanus or Diphtheria toxoid (DT) molecules as carriers (11–14), or LHRH in multiple antigen peptide (MAP) constructs (15). These approaches are impractical for widespread commercial application since passive immunity is inefficient and expensive (16) and the use of peptide–toxoid conjugates and MAP constructs produce variable results (17). On top of that, the GnRH-tetanic toxoid conjugates since their big size can induce anti-haptenic immunosuppression and such process became difficult to reproduce at industrial scale (18).

In order to overcome these limitations, the Heberprovac vaccine candidate was designed, which contains the modified pEHWSYPLRPG GnRH sequence, chemically coupled to the 830–844 T helper epitope of the tetanic toxoid (TT) in the same synthetic process. Such approach breaks immune tolerance to hormone, by eliciting anti-LHRH neutralizing antibodies that induce immunological castration (19). The administration of seven Heberprovac immunizations, followed by radiotherapy in six advanced prostate cancer patients, resulted in 100% immunogenicity, testosterone drop to castration levels, and PSA normalization. These clinical results had never been reported for a GnRH-based vaccine.

MATERIALS AND METHODS

Ethics and Methodological Aspects

The current clinical trial complied with the principles of the Declaration of Helsinki on clinical investigation in humans. It was approved by the Scientific and Ethics Committee of the Marie Curie Oncology Hospital, in Camaguey, Cuba, as well as by the National Regulatory Authority of Cuba (CECMED). The patient’s informed consent was recorded before the study was started. An intermediate endpoint was established to identify the high-risk cases and poorly responding patients, who then received the usual disease treatment as recommended by the medical guidelines. The intermediate evaluation was setup to ensure protection of patients with low immunization response. The adverse events were evaluated by The Common Terminology Criteria for Adverse Events, Version 3.0 (http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf).

Trial Design

It was a single arm, open, prospective study in which a randomized external group of patients with locally advanced and metastatic prostate cancer was used. The main goal of the trial was to evaluate the product safety according to the local and systemic adverse events (AE) and signs of efficacy. The sample size (N) was calculated in 6–8 patients for the immunized and for the external group receiving the standard therapy. During the study, safety and tolerance of the vaccine candidate were monitored by rigorous control of the adverse events, and calculation of the occurrence frequency. The survival of vaccinated patients was compared with a cohort of patients bearing advanced prostate cancer, selected with the same criteria, received the standard anti-hormonal treatment.

Patients and Eligibility

From January to March 2007, eight men diagnosed with advanced (stage 3–4) prostate cancer (TNM classification, 1992) were recruited at the Uro-Oncology Department of the Marie Curie Oncology Hospital in Camaguey, Cuba, based on clinical, biochemical and anatomical-pathological criteria. Previously, all patients signed an informed consent. The prostate biopsy was performed using trans-rectal ultrasound with a biopsy device (ALOKA 2004, Japan). The eligibility criteria also included leukocytes >3.0 × 10^9/L, lymphocytes >1 × 10^9/L, thrombocytes >100 × 10^9/L, and hematocrit >30%. The exclusion criteria for the treatment included previous immunological treatment of up to 2 months before the beginning of the immunization schedule, as well as significant levels of anti-GnRH antibodies, and decompensated chronic diseases (asthma, epilepsy, autoimmune diseases, immunodeficiency, anemia, uncontrolled urinary sepsis and renal, hepatic and cardiovascular diseases) Diagram 1.
Vaccine Composition and Treatment Schedule

The vaccine consist of a mixture of three components: the 27 amino acid GnRHm1-TT peptide synthetized and supplied by The Center of Genetic Engineering and Biotechnology (CIGB), Cuba, in 2.4 mg 2R vials; Montanide ISA 51 VG adjuvant from Seppic, France; and VSSP, a Neisseria meningitidis derived adjuvant produced and supplied by the Center of Molecular Immunology (CIM), Cuba, in 0.8 mg/0.5 mL vials. Before immunization, the peptide was resuspended in VSSP adjuvant and mixed (50:50 v/v) with the Montanide ISA 51VG oil adjuvant, in order to form a water-in-oil emulsion that was added to a total volume of 700 μL, and injected intramuscularly to patients. All patients received seven doses of a vaccine containing 2.4 mg of the peptide, 245 μg of VSSP, and 500 μL of Montanide ISA-51. The first four doses were administered fortnightly, and the remaining three were applied monthly. A month after vaccination ended, a total of 60 Gy radiotherapy (RT) was assessed using a Co-60 radioisotope (Figure 1). The patients’ response to vaccination was evaluated at recruitment, after the fourth and seventh immunizations, and after receiving RT.
Clinical and Complementary Assessment
The patients underwent general physical examination, digital rectal exam (DRE), and laboratory imaging and analysis. The imagenological examination included transrectal and transabdominal ultrasound and bone gammagraphy to determine possible metastases. Blood samples were drawn for routine checkups at recruitment and 15 days after the fourth and seventh immunizations, and after the patients received RT for general clinical laboratory parameters, as well as for anti GnRH antibody titers, using an ELISA kit. For the biochemical and endocrine evaluation, serum PSA was determined by ultra-micro-analysis system (UMELISA, CIE, Cuba) and the testosterone levels were quantified through a radioimmune assay (RIA, CISBIO, France). Since the main goal of the trial was to measure the product safety, the local and systemic adverse events were carefully assessed. Systemic toxicity was evaluated for 72 h after each vaccination. It included measurements of temperature, blood pressure, respiratory frequency 30 min after each injection, and later, every hour during 4 h. The patients completed the physical examination in 72 h, using the standard supervision applied to in-patients, through anti-GnRH quantification plus serum PSA and testosterone determinations.

Long Term Follow-Up of Patients
Follow up was made every 3–4 months for 10 years since the end of the immunization. The parameters evaluated in each medical consultation were the same as for the previous evaluation of patients during the clinical trial development: DRE, anti-GnRH antibodies, serum testosterone and PSA. Imaging methods: Trans-rectal ultrasound (Aloka, Japan) was used at the diagnosis and at the final evaluation for prostate biopsy. In order to look for nodules and metastases, we carried out Tc 99 Gammagraphy scan. After the completion of treatment the patients were followed up for a further period of 10 years. Survival of patients that completed the vaccination schedule was compared with a parallel sample of patients (n = 8) with similar disease status, who received standard anti-hormonal treatment.

Statistics
The data were double entered and validated using Microsoft Access, and then imported into SPSS 13.0, for analysis. The frequency distribution and central tendency and dispersion were estimated by mean standard deviation, median, interquartile range (QR), and the maximum and minimum values (range) for qualitative and quantitative variables.
For each type of adverse event, the frequency distribution (IC 95%) was estimated with the classical and Bayesian statistics. For survival, statistical analysis was carried out using Log Rank test.

RESULTS
Study Population
Between March and July 2007, eight men with confirmed diagnosis of advanced prostate cancer (stages III/IV) were included in the safety study with the vaccine candidate Heberprovac. At the same time, 8 patients with advanced prostate cancer were randomly selected in the uro-oncology service, who began treatment with the standard therapy for prostate cancer and were used as external control group (EG). Tables 1A, B. The age of patients ranged from 63 to 78 years old (71.3 years on average). All patients had high Gleason score confirmed by the histological study. The patients were evaluated at recruitment, after the fourth and last (7th) immunizations, the later after they received the RT (Figure 1). The treatment schedule was completed in 6 patients, who were followed up for recurrence during 10 years (2007–2017) Diagram 1.

Adverse Events
The vaccine was well tolerated despite the presence of side effects and adverse reactions (see below) that coincided with the protocol safety hypothesis. No vaccine-related events exceeded grade II. The intermediate evaluation was made to check safety. Two patients (04 and 06) were removed from the study for presenting signs of clinical and biochemical progression of the disease (interruption criteria).

The observed local and systemic adverse events are summarized in the Table 2. All patients reported local pain at the vaccination site. Three of them developed a slight swelling around the injection site. Other events reported were local redness and swelling, skin atrophy, induration, and erythema. Systemic adverse events included fever, muscle pain and flu-like symptoms in all the six patients that finished the treatment. Late adverse events were mainly associated with the hormone deprivation caused by the vaccine, and included libido.
TABLE 1A | TNM classification and Gleason score of patients included in the Phase I clinical trial with Heberprovac.

| Patient no. | TNM classification | Gleason score |
|-------------|--------------------|---------------|
| MC01        | T3M0N0: Stage III. Prostatic tumor with extracapsular extension to both prostate lobules. No meta, no ganglionar nodules | Prostatic ADC Gleason 9 in all the studied fragments. Predominant pattern 4 |
| MC02        | T3bM0N0: Stage III. Prostatic tumor with extracapsular extension to both prostate lobules. No meta, no ganglionar nodules | Prostatic ADC Gleason 9 in left lobule. Gleason 8. Predominant pattern 4. Right Lobule hyperplastic |
| MC03        | T3bN0M1b Stage IV. Prostatic tumor with extracapsular extension to both prostate lobules. Bone metastases. No ganglionar extension | Prostatic ADC Gleason 8 in 100 % of the simple. Right lobule Hyperplasia |
| MC04        | T4aN0M1b Stage IV. Prostatic tumor with extracapsular extension to both prostate lobules that infiltrate vesical neck, rectus; with bone meta. No ganglionar infiltration | Prostatic ADC. Gleason 10 in all the studied fragment of the right and left lobules |
| MC05        | T3aN0M0. Stage III. Prostatic tumor with extracapsular extension to one prostate lobe. No meta, no ganglionar nodules | Prostatic ADC of all studied fragment of right lobe. Gleason 8. Left lobe, ADC, Gleason 8 in 100% of the samples |
| MC06        | T3bN0M1b Stage IV. Prostatic tumor with extracapsular extension to both prostate lobules. Bone metastases. No ganglionar extension | Undifferentiated Carcinoma of muscle tissue. Gleason 10 |
| MC07        | T3aN0M0 Stage III. Prostatic tumor with extracapsular extension to one prostate lobe. No meta, no ganglionar nodules | Prostatic ADC of right lobe. Gleason 8 in all the samples. Left lobe Hyperplastic |
| MC08        | T3aN0M0 T Stage III. Prostatic tumor with extracapsular extension to one prostate lobe. No meta, no ganglionar nodules. | Prostatic ADC of left lobe. Gleason 10 in 100% of samples. Right lobe hyperplastic. Gleason 6 |

TNM correspond to patient classification according to the American Joint Committee on Cancer (20).

TABLE 1B | TNM classification and Gleason score of patients non-included in the clinical trial that were used as control external group.

| Patient no. | TNM classification | Gleason score |
|-------------|--------------------|---------------|
| EG03        | T4 N1M0: Stage IV. Prostatic tumor with extracapsular extension to both prostate lobules. No meta, ganglionar nodules | Prostatic ADC Gleason 8 in all (4) studied fragments. Predominant pattern 4 |
| EG05        | T4 N0M1: Stage IV prostatic tumor with extracapsular extension to both prostate lobules. Bone metastases, no nodules | Prostatic ADC Gleason 9 in both lobules. Predominant pattern 5 |
| EG06        | T3aN0M0. Stage III. Prostate tumor with perineural and perivascular extension to both prostate lobules. No Bone metastases. No ganglionar extension | Prostatic ADC Gleason 7 in 4 out 5 samples studied. Predominant pattern 4 |
| EG09        | T4b N1M1b Stage IV, prostatic tumor with extracapsular extension to both prostate lobules that infiltrate bladder. Bone metastases and ganglionar infiltration | Prostatic ADC. Gleason 10 in all the studied fragments of the right and left lobules |
| EG11        | T3bN0M0. Stage III. Prostatic tumor with extracapsular extension to both prostate lobules. No metastases, no ganglionar infiltration | Prostatic ADC of the prostate. Right lobe, Gleason 8. Left lobe, Gleason 9 in all the samples |
| EG12        | T3bN1M1b Stage IV. Prostatic tumor with extracapsular extension to both prostate lobules. Bone metastases. No ganglionar extension | Undifferentiated Carcinoma of prostate with muscle tissue infiltration. Gleason 10 |
| EG14        | T3aN0M0 Stage III. Prostatic tumor with extracapsular extension to one prostate lobe. No meta, no ganglionar nodules | Prostatic ADC of right lobe. Gleason 8 in all the samples. Predominant pattern 4 |
| EG17        | T3aN0M0 T Stage III. Prostatic tumor with extracapsular extension to one prostate lobe. No metastases | Prostatic ADC of right lobe. Gleason 9. Predominant pattern 5 |

TNM correspond to patient classification according to the American Joint Committee on Cancer (20).

decrease, sexual dysfunction, breast tenderness and weakness. Remarkably, not a single case of Gynecomastia was observed for the vaccinated group. However, in the case of the control group, it is important to point out that 75% of patients reported hot flushes between 15 and 20 days after the injection of Zoladex, as well as an increase in urinary symptoms after the first two administrations of the GnRH analog. Similarly, symptoms depending of hormonal ablation as asthenia, sexual erectile dysfunction and decreased libido were observed in the 60–100% of patients, respectively (Table 2).
TABLE 2 | Most reported adverse events in Heberprovac vaccinated and control group prostate cancer patients.

| Variables registered by patients | Vaccinated | % | Control Group (%) |
|---------------------------------|------------|---|-------------------|
| Local                            |            |   |                   |
| Pain in the injection site       | 5          | 62.5 | 1                  |
| Edema                           | 5          | 62.5 | 1                  |
| Skin atrophy                    | 4          | 50.0 | 2                  |
| Increase of volume               | 3          | 37.5 | 1                  |
| Erythema                        | 2          | 25.0 | 0                  |
| Induration                      | 4          | 50.0 | 0                  |
| Crusty lesion                   | 4          | 50.0 | 0                  |
| Residual macula                 | 1          | 12.5 | 0                  |
| Scarring reaction               | 1          | 12.5 | 0                  |
| Systemic                        |            |   |                   |
| Fever                           | 6          | 75.0 | 1                  |
| Anemia                          | 1          | 12.5 | 3                  |
| Asthenia                        | 3          | 37.5 | 5                  |
| Bradycardia                     | 1          | 12.5 | 2                  |
| Headache                        | 1          | 12.5 | 2                  |
| Depression                      | 1          | 12.5 | 3                  |
| Decreased libido                | 6          | 75.0 | 8                  |
| Diarrhea                        | 1          | 12.5 | 1                  |
| Sexual erectile dysfunction      | 4          | 50.0 | 7                  |
| Hypertension                    | 3          | 37.5 | 2                  |
| Hot flushes                     | 0          | 12.5 | 6                  |
| Gynecomastia                    | 0          | 0.00 | 5                  |

Clinical and Imaging Evaluations

The evaluation of prostate size according to the DRE at recruitment for the trial showed that 7/8 patients possessed T3 prostate size, while one patient (MC04) displayed T4 prostate; the largest prostate size according to TNM classification (20). These data were confirmed using trans-rectal ultrasound.

Of the eight patients initially included in the trial, six completed the immunization schedule, and in two cases (patients MC04 and MC06) the treatment was interrupted and the patients had to abandon the trial after the intermediate evaluation, due to progression of the disease manifested as elevated PSA and creatinine, urinary obstruction, hydronephrosis, and renal failure that forced them to discontinue immunization.

The completion of treatment with the 7th Heberprovac immunization plus RT, resulted in a significant reduction of the prostate size in the six patients that concluded the full schedule and in the 100% of patients of the control group, considering the prostate size by DRE and trans-rectal ultrasonography.

Transrectal ultrasound data of prostate volume for each patient is summarized in Figure 2. For immunized patients, the most important prostate reduction was observed in the patient MC 03, with 55% prostate reduction. Patients MC 07, MC 05, and MC 02 underwent between 20 and 25% prostate volume reduction, whereas patient MC 08 had around 18% reduction. Patient MC 01 just suffered a 5% of prostate reduction at the time of recruitment.

Anti-GnRH Immune Response and Surrogate Biochemical Markers

Heberprovac is a vaccine candidate designed to generate anti-GnRH antibodies. Such humoral immune response was evaluated at the mid and end stages of the trial and compared with the values at the moment of patient recruitment.

Table 3 shows Testosterone and PSA correspondence with the anti GnRH antibody titers. All patients generated anti-GnRH antibodies after the fourth immunization. Two patients (MC...
03 and MC 05) developed 1:6,400 anti-GnRH antibody titers; three patients (MC 01, MC 02, and MC 07) reached 1:3,200; two patients (MC 04 and MC 06) developed 1:1,600 titers; and one patient (MC 08), developed 1:800 anti-GnRH antibody titers. After completion of the reminder three immunizations, the anti-GnRH immune responses continued increasing and reached 1:25,600 in patient MC 05. Four patients (MC 01, MC 02, MC 03, MC 07) generated 1:12,800 antibody titers. The lowest anti-GnRH antibody response corresponded to patient MC 08, who developed 1:6,400 anti-GnRH titers. As mentioned previously, patients MC 04 and MC 06 showed disease progression, and did not complete the treatment; hence, they were excluded from the final evaluation.

Such anti-GnRH immune responses corresponded with a significant drop in testosterone, found in 3/8 patients (MC 01, MC 03, and MC 08) just 15 days after the fourth immunization. Upon completion of the immunization schedule and the conclusion of the radiotherapy, 100% of the patients that met the criteria of continuity in the trial, underwent testosterone castration under 1 nmol/l (<0.001) (Table 3).

The patient's PSA kinetics was evaluated in parallel during the entire immunization schedule. Such measurements experienced a change from a mean of 26.6 ng/ml at recruitment, to 20.2 ng/ml after the fourth immunization (p > 0.05). The completion of the immunization schedule however, yielded complete PSA normalization in the six patients that concluded the protocol (p < 0.001) (Table 3). It is important to note that the PSA decline started when the anti-GnRH antibodies reached titers similar to or higher than 1:3,000. Figure 3 represents the inverse relation between anti-GnRH antibody titers and the PSA levels. The highest anti-GnRH antibody titers in serum were reached immediately after the end of the vaccination schedule, ∼5 months after the beginning of the trial, with a mean value of 1:14,000.

Accordingly, testosterone values dropped to castration levels, and PSA normalization was observed in all patients at the time of final evaluation. The patient follow up showed that a year after the start of vaccination, the anti-GnRH antibody titers dropped to about half (average 1:6,000) of those seen by the end of the vaccination schedule. The anti-GnRH titers continued to decrease over time, but values remained above background for about 3 years (Figure 5). In accordance with the anti-GnRH seroconversion, during this period the testosterone concentration in serum remained at castration levels, and the PSA levels continued normal. Patients MC 03 and MC 05 showed testosterone and PSA relapsing, which was controlled with additional standard hormonal therapy. However, patient MC 03, responded only temporarily to the additional second line of hormonal ablation, and died 3 and a half years after finishing the treatment.
FIGURE 3 | Anti-GnRH antibody titers and PSA values modifications in patients immunized with Heberprovac. Anti-GnRH antibody titers of 1:3,000 or higher (arrow), correlated with a decrease in the PSA values in all patients. A statistical correlation using a quadratic regression was significant ($R^2 = 0.627$).

FIGURE 4 | Schematic representation of anti-GnRH antibody levels by isotypes tested during the intermediate and final evaluation of prostate cancer patients immunized with Heberprovac. (A) Individual values of anti-GnRH seroconversion by isotypes after the administration of 4 doses of Heberprovac. The most significant anti-GnRH antibody seroconversion were of IgM, IgG1, and IgA isotypes. (B) Individual anti-GnRH seroconversion by isotypes of prostate cancer patients that completed all seven immunizations and received RT. The higher anti-GnRH antibody titers were found for IgG1, IgM, and IgA isotypes, respectively. Statistical significance was calculated using an ANOVA test followed by the Dunn comparison test. The i and f that appear in the legend of (A,B) refer to the intermediate and final evaluations, respectively.
FIGURE 5 | Ten-year follow up of 6 patients that completed the trial schedule with Heberprovac and received RT. The colored lines and each point represent the mean of the anti GnRH antibody titres (black), Testosterone values (nmol/L), (red), and PSA levels (ng/mL), (blue) at different moments of the trial. Maximal antibody titers corresponded with the Testosterone decrease to castration levels and PSA normalization between 5 and 6 months after the beginning of the trial. Note that, after an initial peak, the antibody titers dropped to about 50% 1 year after the treatment was completed, and were nearly zero at the end of the second year. However, testosterone continued at castration levels and PSA stayed normalized until the third year after treatment. Peaks of testosterone and PSA were observed between years 3 and 5 and corresponded to patients relapsed. Prism Graph Pad v6.1 was used for graph.

Also, from 3.5 to 5 years post-immunization, an increase in the testosterone levels was observed in patients MC 01, MC 07, and MC 08 (Figure 5). But it just raised the PSA values in patient MC 05, who responded very fast to the use of GnRH analog Zoladex.

The overall survival data of this study are summarized in the Figure 6. For the immunized group, patient MC 07, who maintained prostatic disease clinically and biochemically controlled, developed a primary lung cancer and died several months later. By the ninth year after the treatment, patient MC 08, who had never manifested PSA relapse or required any additional treatment for prostate cancer, died of pneumonia at age 82.

Ten years after the end of the treatment with Heberprovac, 3 out of 6 patients that completed the treatment schedule are alive and have a clinically and biochemically controlled disease (Diagram 1). However, in the case of the control group that received standard anti-hormonal treatment, only 1 out 8 patients (12.5%) survive and keep hormone sensitiveness (Figure 6). The first patient of control group died after the third year (EG 09) as result of bone metastases and anemia. Patients EG 05 and EG 12 fell in a state of castration resistance and died at 5 and 7 years after the disease diagnosed, respectively. Patients EG 03 and EG 06 died from non-related prostate disease after 8 and 9 years of the treatment began, respectively. Finally, patient EG 11 suffered brain metastases and patient EG 14 was affected by bone metastases and kidney infiltration that generated renal insufficiency. Both patients succumbed 10 years after finished the treatment.

DISCUSSION

The combined use of adjuvant hormone and radiation therapies to treat high-risk prostate cancer patients has improved significantly results, with about 80% of patients disease-free (and no PSA failure) for 5 years (21).

The Gonadotropin-releasing hormone (GnRH) is critical for the normal functioning of the reproductive system. The administration of either polyvalent or monoclonal anti-GnRH antibodies in males, leads to decreased testicular size, cessation of spermatogenesis, and a severe reduction of testosterone levels, as does immunization with the GnRH-carrier conjugates (17, 22).

A number of studies have shown that the GnRH vaccines have promising application for managing hormone-dependent cancers (prostate and breast cancer) (23–25). However, the
clinical application of these synthetic vaccines requires the availability of a powerful adjuvant to enhance antibody responses that effectively block hormone-receptor binding, for instance using GnRH analogs conjugated to bacterial toxoids, such as diphtheria (DT) or tetanic toxoid (TT) (26).

This paper describes a novel GnRH vaccine candidate (Heberprovac), which overcomes the limitations reported for other vaccine candidates in terms of anti-GnRH antibody responses and their efficacy. The fact that 100% of patients developed significant anti-GnRH antibody titers, and in turn all of them normalized or decreased PSA below 4 ng/mL during the final evaluation, represents an important achievement in relation to all the previous vaccine candidates based on GnRH (18, 27). Indeed, this is the first time that such efficient antibody responses have been reported using a GnRH-based vaccine.

The improved results provided by Heberprovac, could be partially considered as a consequence of amino acid change of L-Glycin by L-proline at the sixth position of the native GnRH that breaks the natural “U” conformation of the GnRH peptide. This change, along with the incorporation of the 830–844 TT epitope, leads to the formation of a longer and more rigid molecule that impairs hormone-receptor interaction and supports a better antigen processing and presentation thanks to its high promiscuity to existing haptenic molecules of different origins (12, 19, 28).

In addition, Heberprovac combines the GnRHM1-TT peptide formulated with the adjuvant Montanide ISA 51 (oil adjuvant) and VSSP, that belongs to the new generation of adjuvants based on pathogen-related molecules identified as danger signals recognized by the innate immune system (29). VSSP is proved to have the ability to activate mouse and human dendritic cells, in vitro and in vivo, with the corresponding IL-12p40/p70, TNF-α, and IL-6 production (30, 31).

Since Heberprovac effectiveness will depend mainly on the anti-hormonal effects caused by anti-GnRH antibodies capable of inducing immunocastration, the antibody titers, isotype maturity, and antibody affinity should correlate with such vaccine effects.

As expected, most anti-GnRH antibodies elicited after the first immunizations were of IgM isotype. At the end of immunization schedule, the antibodies switched to IgG1 and IgG2 subtype patterns in most patients. Several reports have shown that adjuvance of peptide vaccines with Montanide ISA 51 VG induces powerful antibody responses with a mixed Th1/Th2 profile, thanks to their capacity to expand lymphocyte subpopulations, particularly IFNγ that produces CD4 and CD8 T cells [production (30, 31)].

Regardless of the anti-GnRH antibody isotype proportion that prevailed in each patient, the testosterone values dropped significantly in all the cases at the end of the immunization schedule and radiotherapy. Interestingly, when the anti-GnRH antibody production reached titer ≥1:3,000, the PSA levels dropped to normal values in all the patients. This correlation could represent a prognostic indicator of patient responses to immunization with Heberprovac. However, further studies including a larger number of patients are required.

The high anti-GnRH immune response and the drastic reduction of testosterone levels in patients with advanced prostate cancer induced by Heberprovac in the current study, has not been reported before for similar candidates in clinical trials (11–13, 18, 28). Nevertheless, the most striking result of this study is, undoubtedly, the higher rate of survival after a 10-year follow up (see below). Remarkably, the immunological and endocrine parameters correlated with normalization of PSA serum levels in 100% of patients, elimination of urinary obstruction symptoms, and normalization of prostatic signs, according to the data obtained with the DRE and transrectal ultrasonography of the 6 patients who completed the clinical study. Interestingly, a year after the end of the trial, the breast tenderness observed during the first months disappeared, seemingly in relation to the discrete increase in the testosterone levels. A decrease in sexual libido was maintained while testosterone in serum remained at castration levels, and it was more evident in older patients (MC 02, MC 05, and MC 07). However, two of these patients had prior episodes of sexual erectile dysfunction. The remaining patients, including the MC 03 patient, who died of metastatic lesions 3 and a half years following treatment completion, showed a partial recovery of their sexual libido when the testosterone levels exceeded 5 nmol/L (data not shown). It was remarkable that, throughout the study, none of the patients suffered gynecomastia or hot flushes. However, the control group that received the standard antihormonal treatment, although it did not manifest any of the symptoms associated with the inflammatory response generated by the vaccines, showed a profuse symptomatology of testosterone suppression as the decrease in sexual libido, hot flushes, erectile sexual dysfunction and muscle weakness in the 60–100% of the patients, indistinctly. The occurrence of these adverse events, observed in the control group and commonly reported during hormonal therapy (32–35), were not observed with Heberprovac immunization. This is likely due to the gradual testosterone decrease induced by the vaccine in contrast to the rapid castration induced by analogs and antagonists of GnRH (36–40).

The long-term evaluation of patients immunized with Heberprovac, demonstrated a 50% survival in a 10 years follow up. In contrast, the parallel control group of patients receiving standard therapy for advanced prostate cancer demonstrated a significantly lower survival rate (12.5%) in the same period (p < 0.05) (Figure 6). We believe that the slow and progressive form of hormonal ablation produced by Heberprovac vaccination could be a determining factor in a longer delay in the transition from prostatic tumors to castration resistance (CRPC) and hence in the superior survival of Heberprovac vaccinated patients. Other aspects such as the value that the use of adjuvants such as VSSP could have in the generation of an immune spreading against the prostate tumor should also be explored.

Concerning long-term disease control in the vaccinated patients, only one patient (MC 03) died before 5 years of treatment. This case was a patient with metastatic prostate cancer at recruitment, and persistent symptoms of bone pain who, nevertheless, showed a vigorous immune response after vaccination that corresponded with a decrease in testosterone to castration levels, PSA normalization, and prostate size reduction,
as shown by DRE and trans-rectal ultrasound. Besides this case, only one patient (MC 05) experienced a biochemical recurrence in the fourth year of the clinical trial and required hormonal treatment. Patients MC 01 and MC 08 showed a testosterone recovery of 10 and 15 nmol/L, respectively, however, they maintained normal levels of PSA, and did not require any additional treatment until 6.5 and 7 years.

Patients MC 07 and MC 02, both over 80 years old, died seven and 9 years after the start of the clinical trial, respectively, by causes unrelated to prostate cancer and its treatment. In both cases the patients exhibited complete disease control at the time of death, and never required additional hormone manipulation or another type of therapeutic strategy.

Altogether, these results are suggestive of a positive impact of vaccination with Heberprovac in overall patient survival compared with those receiving the standard treatment. Response to the vaccine correlated with the antibody titers raised against GnRH as well as with PSA reduction and castration levels of serum testosterone. Nevertheless, the value of such parameters as biomarkers of response need to be further confirmed in a future clinical trial with a larger cohort of prostate cancer patients.

**AUTHOR CONTRIBUTIONS**

JJ, RR, FF, IB, MDC, LC, CV, EB, EP, RBa, RBr, GG, AHG, AnC, AdC, ARa, AC-A, LH, and FS: conception and design of the study and writing and revision of the manuscript. LG, LP-F, ARo, AHG, OR, ML, MMed, LdQ, AA, CM, MMen, MMa, GM, AG, PR, RM, YF, MC, HT, DB, KC, PS, MQ, VM, MA, NA, CC, SA, IV, LA, ErR, ELR, PCe, PCa, MCS, IF, and LF: clinical trial assessment.

**ACKNOWLEDGMENTS**

This study was conducted by the Center for Genetic Engineering and Biotechnology of Camaguey, Cuba. We are most grateful to the participating patients and their families, as well as the staff of all institutions involved in this study.

**REFERENCES**

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res (1941) 1:293–7.

2. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Cosedex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol. (1994) 67:10–4. doi: 10.1159/000475425

3. Francini E, Taplin ME. Prostate cancer: developing novel approaches to castration-sensitive disease. Cancer. (2017) 1:29–42. doi: 10.1002/cncr.30329

4. Öhlmann CH, Thelen P. Antihormonal therapy in prostate cancer: Side effects. Urologie A (2017) 36:465–71. doi: 10.1007/s00120-017-0340-5

5. Hoda MR, Kramer MW, Merseburger AS, Cronauer MV. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother. (2017) 18:105–13. doi: 10.1080/14656566.2016.1258058

6. Okamura T, Akita H, Yamada K, Kobayashi D, Hirose Y, Kobayashi T, et al. Therapeutic results in elderly patients with prostate cancer: chronological comparison in a single community hospital. J Rural Med. (2016) 11:59–62. doi: 10.2185/jrjm.2916

7. Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacourciere Y, et al. Treatment of prostate cancer with gonadotropin releasing hormone agonists. Endocrinol Rev. (1986) 7:67–74. doi: 10.1210/edrv-7-1-67

8. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I. Equivalent and fully synthetic peptide-carrier constructs targeting GnRH. Vaccine (2004) 22:1300–13. doi: 10.1016/j.vaccine.2003.08.044

9. Guan C, Garza-Flores J, Menjivar M, Gutiérrez-Najar A, Pal R, Talwar GP. Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women. Fertil Steril. (1997) 67:404–7. doi: 10.1016/S0016-5432(97)81932-2

10. Silversides DW, Murphy BD, Misra V, Mapletoft RJ. Monoclonal antibodies against LHRH: development and immunoactivity in vivo and in vitro. J Reprod Immunol. (1995) 31:171–84. doi: 10.1016/0165-0378(95)80071-3

11. Beekman NJ, Schaaper WM, Turkstra JA, Meloen RH. Highly immunogenic and fully synthetic peptide-carrier constructs targeting GnRH. Vaccine (1999) 17:2043–50. doi: 10.1016/S0264-410X(98)00407-1

12. Finstad CL, Wang CY, Kowalsky J, Zhang M, Li M, Li X, et al. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. Vaccine (2004) 22:1300–13. doi: 10.1016/j.vaccine.2003.08.044

13. Gual C, Garza-Flores J, Menjivar M, Gutiérrez-Najar A, Pal R, Talwar GP. Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women. Fertil Steril. (1997) 67:404–7. doi: 10.1016/S0016-5432(97)81932-2

14. Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, et al. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer (2000) 83:443–6. doi: 10.1054/bjc.2000.1315

15. Schutz M-P, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

16. Etlinger HM, Gillessen D, Lahm HW, Matile H, Schönfeld HJ, Trzeciak A. Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women. Fertil Steril. (1997) 67:404–7. doi: 10.1016/S0016-5432(97)81932-2

17. Schutze M-P, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

18. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

19. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

20. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

21. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

22. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

23. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

24. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

25. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.

26. Fleig I, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol. (1985) 135:2319–22.
tumor growth in orthotopic prostate cancer mouse model. *Cancer Lett.* (2008) 259:240–50. doi: 10.1016/j.canlet.2007.10.011

24. Fromme B, Eftekhari P, Regenmortel M, van Hoebeke J, Katz A, Millar R. A novel retro-inverso gonadotropin releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. *Endocrinology* (2003) 7:3262–9. doi: 10.1210/en.2002-221135

25. Hsu CT, Ting CY, Ting CJ, Chen TY, Lin CP, Whang-Peng J, et al. Vaccination against gonadotropin releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. *Cancer Res.* (2000) 60:3701–5.

26. Ferro VA, Stimson WH. Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. *Vaccine* (1998) 16:1095–103. doi: 10.1016/S0264-410X(98)00104-7

27. Parkinson RJ, Simms MS, Broome P, Humphreys JE, Bishop M. A vaccination strategy for the long-term suppression of androgens in advanced prostate cancer. *Eur Urol.* (2004) 45:171–5. doi: 10.1016/j.eurouro.2003.10.007

28. Talwar GP, Hemant Vyas HK, Purswani S, Gupta JC. Gonadotropin-releasing hormone/human chorionic gonadotropin β based recombinant antibodies and vaccines. *J Reprod Immunol.* (2009) 83, 158–63. doi: 10.1016/j.jri.2009.08.008

29. Matzinger P. Tolerance, danger, and the extended family. *Annu Rev Immunol.* (1994) 12:991–1045. doi: 10.1146/annurev.iy.12.040194.005015

30. Talwar GP, Hemant Vyas HK, Purswani S, Gupta JC. Gonadotropin-releasing hormone/human chorionic gonadotropin β based recombinant antibodies and vaccines. *J Reprod Immunol.* (2009) 83, 158–63. doi: 10.1016/j.jri.2009.08.008

31. Junco JA, Rodríguez, Fuentes F, Bover E, Pimentel E, Basulto F, et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. *Mol Pharm.* (2011) 7:104–16. doi: 10.1021/mp100178k

32. Junco JA, Millar RP, Fuentes F, Bover E, Pimentel E, Basulto F, et al. Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model. *Oncof. Lett.* (2016) 12:963–70. doi: 10.3892/ol.2016.4679

33. Gupta SK, Shrestha A, Chaudhary D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. *Int J Cancer* (2016) 138:1563–70. doi: 10.1002/ijc.30403

34. Junco JA, Rodríguez, Fuentes F, Bover E, Pimentel E, Basulto F, et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. *Mol Pharm.* (2011) 7:104–16. doi: 10.1021/mp100178k

35. Junco JA, Millar RP, Fuentes F, Bover E, Pimentel E, Basulto F, et al. Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model. *Oncof. Lett.* (2016) 12:963–70. doi: 10.3892/ol.2016.4679

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.